NCT04938752View on ClinicalTrials.gov

Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects (DA-2811)

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 8, 2021

Primary Completion Date

August 20, 2021

Study Completion Date

August 20, 2021

Conditions
Healthy
Interventions
DRUG

DA-2811

single dose administration (one tablet once a day)

DRUG

DA-2811-R

single dose administration (one tablet once a day)

Trial Locations (1)

Unknown

Seoul National University Bundang Hospital, Gyeonggi-do

All Listed Sponsors
lead

Dong-A ST Co., Ltd.

INDUSTRY